Crizotinib Capsules
Form: Oral Capsules
Strength: 200 mg, 250 mg
Reference Brands: Xalkori® (US & EU)
Category: Oncology Cancer Care
Crizotinib Capsules are a targeted therapy used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive cancers, as well as anaplastic large cell lymphoma (ALCL). As a tyrosine kinase inhibitor (TKI), Crizotinib blocks the activity of abnormal proteins responsible for cancer cell growth. Marketed under Xalkori®, Crizotinib is available in 200 mg and 250 mg oral capsule strengths. Manufactured under GMP-compliant conditions, it offers a reliable solution for pharmaceutical distributors targeting US and EU oncology markets, providing effective treatment options for precision cancer medicine.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details Get Enquiry
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details Get Enquiry
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details Get Enquiry
Ifosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details Get Enquiry